Expression of IL-17 on Breast Cancer Mice Treated by Combination of Phyllanthus Urinaria and Catharanthus roseus Extract

Authors

  • Aya Shofiyah Biology Master Program, Faculty of Mathematics and Natural Sciences, University of Brawijaya, Malang, Indonesia
  • M. Sasmito Djati Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya. Jl. Veteran, Malang 65145, East Java, Indonesia
  • Muhaimin Rifa'i Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Brawijaya. Jl. Veteran, Malang 65145, East Java, Indonesia

DOI:

https://doi.org/10.21776/ub.jels.2022.012.02.05

Abstract

This study aimed to evaluate the effect of combination Phyllanthus urinaria and Catharanthus roseus in breast cancer mice based on the expression of IL-17. 7,12-Dimethylbenz(α)anthracene (DMBA) was injected intraperitoneally into normal mice at dose 1.5 mg.kg-1 weight to obtain breast cancer mice. Total of 24 experimental mice divided into normal mice (N), breast cancer mice (K), breast cancer mice with cisplatin (C) treatment (5 mg.kg-1 weight), breast cancer mice with combination extract Dose 1 (P. urinaria 500 mg.kg-1 weigt + C. roseus 15mg.kg-1 weight), breast cancer mice with combination extract Dose 2 (P. urinaria 1000 mg.kg-1 weight + C. roseus 75mg.kg-1 weight), and breast cancer with combination extract Dose 3 (P. urinaria 2000 mg.kg-1 weight + C. roseus 375 mg.kg-1 weight). Cheral was given orally for 14 days. The level of IL-17 was evaluated by flow cytometry analysis. The combination can suppress the expression of IL-17 which down regulation of IL-17 indicate a good prognosis for the breast cancer mice, for 6.17% in breast cancer condition to 0.93% with Dose 3 treatment. The combination can be used as immunomodulatory agent in humoral immunity through the regulation of IL-17. Keywords: Breast cancer, Catharanthus roseus, IL-17, Phyllanthus urinaria

Downloads

Published

2022-06-30

Issue

Section

Articles